

## CORRECTIONS

In the Review Article entitled “Practical aspects of new oral anticoagulant use in atrial fibrillation” published in the March 2014 issue (Undas A, Pasierski T, Windyga J, Crowther M. Practical aspects of new oral anticoagulant use in atrial fibrillation. *Pol Arch Med Wewn.* 2014; 124: 124-135.), in table 2, the following values: 0.65; 3.32%/y (399/6076); and 0.93 (0.81–1.07) [0.32]<sup>b</sup> in columns “Rate ratio (95% CI) [P value]”; “Major bleeding, %/y (n/N)”; and “Rate ratio (95% CI) [P value]”, respectively, should be aligned with “dabigatran, 150 mg bid”. The primary outcome: stroke or systemic embolism for apixaban in ARISTOTLE trial should read “1.27%/y (212/9120)” rather than “1.27%/y 9212/9120). In table 3, the line reading “congestive heart failure/left ventricular 1” under “CHA2DS2-VASc” should read “congestive heart failure/left ventricular dysfunction 1”. The line reading “dysfunction 1” should be deleted. In table 4, the entry “acceptable INR values” is duplicated. In the bottom row, “Acceptable INR values” should read “number of days without VKA if the initial INR is >3.5”. The article is correct at [www.pamw.pl](http://www.pamw.pl).